EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks

Amirah E-E Aly, Nicholas S Caron, Hailey Findlay Black, Mandi E Schmidt, Christine Anderson, Seunghyun Ko, Helen J E Baddeley, Lisa Anderson, Lorenzo L Casal, Reza S M Rahavi, Dale D O Martin, Michael R Hayden

Journal of Controlled Release · 2023

DOI: 10.1016/j.jconrel.2023.07.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Amirah E-E Aly und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research Institute, Department of Medical Genetics, University of British Colu…. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Huntington Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lowering mutant huntingtin (mHTT) in the central nervous system (CNS) using antisense oligonucleotides (ASOs) is a promising approach currently being evaluated in clinical trials for Huntington disease (HD). However, the therapeutic potential of ASOs in HD patients is limited by their inability to cross the blood-brain barrier (BBB). In non-human primates, intrathecal infusion of ASOs results in limited brain distribution, with higher ASO concentrations in superficial regions and lower concentrations in deeper regions, such as the basal ganglia. To address the need for improved delivery of ASOs to the brain, we are evaluating the therapeutic potential of apolipoprotein A-I nanodisks (apoA-I NDs) as novel delivery vehicles for mHTT-lowering ASOs to the CNS after intranasal administration. Here, we have demonstrated the ability of apoA-I nanodisks to bypass the BBB after intranasal delivery in the BACHD model of HD. Following intranasal administration of apoA-I NDs, apoA-I protein levels were elevated along the rostral-caudal brain axis, with highest levels in the most rostral brain regions including the olfactory bulb and frontal cortex. Double-label immunohistochemistry indicates that both the apoA-I and ASO deposit in neurons. Most importantly, a single intranasal dose of apoA-I ASO-NDs significantly reduces mHTT levels in the brain regions most affected in HD, namely the cortex and striatum. This approach represents a novel non-invasive means for improving delivery and brain distribution of oligonucleotide therapies and enhancing likelihood of efficacy. Improved ASO delivery to the brain has widespread application for treatment of many other CNS disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseHuntington DiseaseAnimalsApolipoprotein A-IBrainBlood-Brain BarrierHuntingtin Protein

Stichwörter der Autor:innen

Antisense oligonucleotideApolipoproteinBBBHuntington diseaseIntranasalNanodiskNon-invasive

Substanzen

Oligonucleotides, AntisenseApolipoprotein A-IHuntingtin Protein

Autor:innen und Institutionen

  • Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.
  • Centre for Molecular Medicine and Therapeutics, Vancouver, BC V5Z 4H4, Canada.
  • Michael Cuccione Childhood Cancer Research Program, British Columbia Children's a Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.
  • Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada; Department of Biology, University…
  • Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada. Electronic address: mrh@cmmt.ubc.…

Zitieren

APA

Aly, A. E., Caron, N. S., Black, H. F., Schmidt, M. E., Anderson, C., Ko, S., Baddeley, H. J. E., Anderson, L., Casal, L. L., Rahavi, R. S. M., Martin, D. D. O., & Hayden, M. R. (2023). Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.07.027

Vancouver

Aly AE, Caron NS, Black HF, Schmidt ME, Anderson C, Ko S, et al. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.07.027

BibTeX
@article{Aly2023,
  author = {Aly, Amirah E-E and Caron, Nicholas S and Black, Hailey Findlay and Schmidt, Mandi E and Anderson, Christine and Ko, Seunghyun and Baddeley, Helen J E and Anderson, Lisa and Casal, Lorenzo L and Rahavi, Reza S M and Martin, Dale D O and Hayden, Michael R},
  title = {Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks},
  journal = {Journal of Controlled Release},
  year = {2023},
  doi = {10.1016/j.jconrel.2023.07.027}
}
Kostenlos starten →